Oct. 6, 2009 (PR Newswire) --
REDWOOD CITY, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from two studies at the American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium, taking place October 8 through October 10 at the San Francisco Marriott in San Francisco, California. Both studies analyze Oncotype DX®, the company's multi-gene expression test that physicians use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.
Presentation details are as follows (all times are Pacific Daylight Time):
- Friday, October 9 (12:30 p.m. - 1:30 p.m. PT and 5:30 p.m. - 7 p.m. PT)
Poster Board #A15
Poster presentation: "Biopsy Cavities in Breast Cancer Specimens:
Impact on Gene Expression Profiles and Recurrence Risk Assessment"
Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer
Center at the University of California, San Francisco
Location: Golden Gate Hall
- Friday, October 9 (12:30 p.m. - 1:30 p.m. PT and 5:30 p.m. - 7 p.m. PT)
Poster Board #A19
Poster Presentation: "A Study of the Oncotype DX(R) Recurrence Score(R)
as a Prognostic Factor in Early Stage Breast Cancer in the Japanese
Population"
Presenter: Masakazu Toi, M.D., Ph.D, Department of Surgery, Graduate
School of Medicine, Kyoto University
Location: Golden Gate Hall
About Oncotype DX®
The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer assay has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of May 2009, more than 8,000 physicians had ordered more than 100,000 tests in over 40 countries, and both Medicare and private health plans covering over 90 percent of U.S. insured lives, provide reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive.
